Imjudo (Tremelimumab-Actl) for Lung Cancer

Overview
Imjudo is approved by the U.S. Food and Drug Administration (FDA) in combination with durvalumab and platinum-based chemotherapy for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) without specific genetic mutations. Imjudo is also known by its drug name, tremelimumab-actl.
Imjudo is a human monoclonal antibody that targets the activity of CTLA-4, a protein that decreases the immune system’s activity. By blocking CTLA-4, Imjudo enhances the body’s immune response against cancer cells.

How do I take it?
Prescribing information states that Imjudo is administered as an intravenous infusion over 60 minutes. For metastatic NSCLC, individuals generally receive doses every three weeks in combination with durvalumab and platinum-based chemotherapy for four cycles. Following this, they continue to receive durvalumab every four weeks along with pemetrexed therapy, and a fifth dose of Imjudo is given at Week 16. This medication should be administered exactly as prescribed by a health care provider.

Side effects
Common side effects of Imjudo among people being treated for NSCLC include nausea, fatigue, musculoskeletal pain, decreased appetite, rash, and diarrhea.

Rare but serious side effects may include immune-mediated adverse reactions such as pneumonitis (lung inflammation), colitis (inflammation of the colon), hepatitis (liver inflammation), endocrinopathies (hormonal disorders), nephritis (kidney inflammation) with renal dysfunction, dermatologic (skin) reactions, and pancreatitis (inflammation of the pancreas). Infusion-related reactions and embryo-fetal toxicity (harm to an embryo, fetus, or unborn baby) are also possible.

For more information about this treatment, visit:

Label: Imjudo — Tremelimumab Injection, Solution — DailyMed

Imjudo — Drugs.com